Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

OHSU Expert Co-Authors Study Finding Treatment for Rare Lung Disease

12.04.2011
An Oregon Health & Science University researcher has co-authored an international study that revealed a drug approved to prevent rejection in organ transplant patients helped treat a rare lung disease in women.

The life-threatening disease has no cure and, until now, no known treatment.

The clinical trial of the drug -- called sirolimus -- was the first randomized, controlled study designed to develop a therapy for the lung disease, lymphangioleiomyomatosis, or LAM.

LAM is a progressive, cystic lung disease that occurs almost exclusively in women. In LAM, smooth muscle cells grow uncontrollably and spread to restricted areas in the body, including the lungs, lymph nodes and vessels and kidneys, limiting the flow of air, blood and immune system fluid, or lymph.

Shortness of breath and recurrent lung collapse are common in patients with LAM; until now, lung transplantation has been the only hope for patients who progress to respiratory failure. LAM affects about five per million people.

The positive results from the clinical trial of sirolimus, also known as rapamycin, were reported last month in the online edition of the New England Journal of Medicine.

The lead investigators in the study were from the University of Cincinnati and Cincinnati Children's Hospital Medical Center. Alan Barker, M.D., an OHSU expert in rare lung diseases, was a principal investigator in the study.

The study was conducted at 13 institutions throughout the United States, Canada and Japan. The only West Coast institutions involved in the study were OHSU and the University of California at Los Angeles. Research subjects from the Northwest and northern California were enrolled in the study at OHSU.

Eighty-nine women with LAM, aged 18 or older, participated in the study. Some were treated with sirolimus; others were given a placebo.

The researchers found that sirolimus stabilized lung function and was associated with improvement in measures of functional performance and quality of life.

OHSU's Barker said that the study results point to a potential treatment for LAM. The results are also important because they could serve as a model for treating common types of cancers.

"Like cancer, LAM occurs when cells grow out of control; in LAM's case, cells in the blood vessels and breathing passages in the lung grow out of control," Barker said. “This drug stopped that abnormal growth of cells."

Barker said that OHSU also will be part of a follow-up study that examines the effectiveness of another drug in treating LAM.

The sirolimus study was funded by the National Institutes of Health's Office of Rare Disease Research; the Food and Drug Administration; the LAM Foundation; the Japanese Ministry of Health, Labour and Welfare; the Canadian Institutes of Health Research; Cincinnati Children’s Hospital, the University of Cincinnati; the Tuberous Sclerosis Alliance Rothberg Courage Award; and Vi and John Adler and the Adler Foundation.

Pfizer, maker of sirolimus, provided the drug and financial support but had no role in study design, conduct, analysis or reporting.

About OHSU
Oregon Health & Science University is the state’s only health and research university, and only academic health center. As Portland's largest employer and the fourth largest in Oregon (excluding government), OHSU's size contributes to its ability to provide many services and community support activities not found anywhere else in the state. It serves more than 184,000 patients, and is a conduit for learning for more than 3,900 students and trainees. OHSU is the source of more than 200 community outreach programs that bring health and education services to each county in the state.

Todd Murphy | EurekAlert!
Further information:
http://www.ohsu.edu

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>